INTRODUCTION
Four different hexokinases (EC 2.7.1.1) catalyse the phosphorylation of glucose in mammalian tissue [1] . In human erythrocytes hexokinase type I is the predominant isoenzyme, but in recent years we [2, 3] and others [4] have clearly shown that this glucose-phosphorylating activity consists of at least three different subtypes (Ta, Tb and Ic) that differ in isoelectric points and show pronounced cell-age-dependent modifications [3] . Although several pieces of evidence [5] [6] [7] seem to indicate that all hexokinase I subtypes are under the control of the same gene, the origin of these multiple forms is still an open question. Furthermore, it has been shown that hexokinase type I from human heart [8] and human placenta [9] is present in two subtypes with different Mr values in SDS/polyacrylamide-gel electrophoresis, but with identical isoelectric points. This fact raises the question whether the erythrocyte enzyme is present as two components and what relationship exists, if any, between the microheterogeneity in charge previously reported [2] [3] [4] and the differences in Mr as seen in other human hexokinases I [8, 9] . This question could in principle be solved by the purification of the human erythrocyte enzyme to homogeneity, but this does not seem feasible, since all the purification procedures so far reported [10] [11] [12] 
Assays
Hexokinase activity was measured as described in ref. [9] , protein was determined by the method of Bradford [14] and haemoglobin was determined as described in ref. [5] . Purification of hexokinase Hexokinase type I from human placenta was purified as described in ref. [9] to a specific activity of 190+5 units/mg of protein and showed two protein bands (Mr 112000 and 103000) upon SDS/polyacrylamide-gel electrophoresis.
Hexokinase from human erythrocytes was partially purified up to (NH4)2SO4 fractionation in the procedure described in ref. [3] and then by Matrex Gel Red A chromatography, affinity chromatography on immobil-ized glucosamine and Matrex Gel Blue A chromatography as described for the placenta enzyme [9] . The final specific activity ranged between 25 and 30 units/mg of protein in three different preparations with yields in the range 10-20%, representing a higher-than-35000-fold purified enzyme that was contaminated by several proteins as evidenced by SDS/polyacrylamide-gel electrophoresis. Antibodies An antiserum against homogeneous hexokinase I from human placenta was raised in rabbits. Immunization was by the injections of 100 ,tg of protein at 10-day intervals, with the first injection being in compete Freund's adjuvant. IgGs were prepared from serum of immunized and control rabbits by chromatography on immobilized Protein A and elution by 0.1 M-sodium citrate buffer, pH 3.5. A 50,g portion of anti-hexokinase IgG was found to be able to inactivate 0.25 unit of hexokinase activity. No inactivation occurred with IgG from normal rabbits. Purified IgGs were coupled to the glutardialdehyde-activated affinity adsorbent according to the instructions of the manufacturers and equilibrated in 0.9 % NaCl solution.
Separation of hexokinases Ia, lb and Ic
Hexokinases Ta, lb and Ic were obtained by h.p.l.c. ion-exchange chromatography from human erythrocyte lysate and the (NH4)2SO4 fraction (see above). Briefly, 0.5 ml samples were applied on a Bio-Gel TSK DEAE 5PW column (75 mm x 7.5 mm internal diam.) equilibrated in 5 mM-sodium/potassium phosphate buffer, pH 7.5, containing 3 mM-2-mercaptoethanol and 5 mMglucose, connected to a Beckman h.p.l.c. system and operated at 1 ml/min. The column was developed by a 300 ml linear gradient of 0-0.4M-KCI in the equilibrating buffer, and 1 ml fractions were collected and assayed for hexokinase activity. The fractions containing hexokinases Ta, Tb and Ic were pooled separately, dialysed and concentrated by ultrafiltration and used for electrophoresis and electroblotting experiments as previously described [9] .
RESULTS

Immunological properties of erythrocyte, hexokinases
In previous studies [7] from an (NH4)2SO4 fraction [3] of erythrocyte lysate was chromatographed first on immobilized IgG from normal rabbits and then on a 2 ml column of immobilized anti-(hexokinase I) IgG. The column was then washed with 300 (w/v) NaCl solution until protein absorbance at 280 nm was less than 0.005, and the bound enzyme was eluted with 0.1 M-sodium citrate buffer, pH 3.5. Eluted proteins were dialysed against 200 vol. of 10 mMsodium phosphate buffer, pH 7.5, containing 3 mM-2-mercaptoethanol, concentrated in a Savant concentrator, separated by SDS/polyacrylamide-gel electrophoresis and electroblotted as described in ref. [9] . Fig. 1(b (Fig. 2) . The procedure required to remove the bulk of the haemoglobin (batch chromatography on DEAE-Sephadex A-50) caused some loss of hexokinase Ic, as previously shown [3] ; however, this is not a serious problem, since pooled fractions of each hexokinase subtype provided enough material to show that hexokinases Ia, Tb and Ic have the same Mr of 1 12000 (Fig. 3) Fig. 2 and immunoblot was performed as in Fig. 1 .
Vol. 254 fully. We utilized a procedure that removed the bulk of haemoglobin by DEAE-Sephadex A-50 as described in ref. [3] and then utilized the strategy we have developed to purify hexokinase I from human placenta. A 1-litre volume of blood was commonly employed as starting material; however, we obtained enzyme preparations always contaminated by proteins as detected by SDS/ polyacrylamide-gel electrophoresis. However, immunoblotting was performed on these samples and only one polypeptide was always detected (Fig. 4) . Since the antibody employed was a polyclonal one able to detect denatured and proteolysed hexokinase (results not shown), we can conclude that in erythrocytes hexokinase type I consists of only one polypeptide of Mr 112000, in contrast with that previously found for placenta and heart hexokinase I [8, 9] .
DISCUSSION
Many reports in the last years have already shown that the occurrence of enzymes in multiple molecular forms should no longer be considered an exception, but rather a common feature of biological systems. Among the several mechanisms that could lead to the appearance of enzyme microheterogeneity, two seem to involve human hexokinase I. Independent studies in our [3] and other laboratories [4] have shown that hexokinase I in human erythrocytes, as well as in the erythrocytes of other mammalian species [15] , is present in multiple molecular forms that differ in charge. More recently human heart hexokinase type I [8] and human placenta hexokinase I [9] have been isolated in homogeneous form and found to be present in two different subtypes with Mr values of 112000 and 103 000 [8] . This fact prompted us to reinvestigate the microheterogeneity of human erythrocyte hexokinase to see whether or not any relationship exists between charge and Mr heterogeneity in hexokinase I. The approach that we used to study this problem was based on the high sensitivity and specificity of the immunoblotting techniques. As we have reported in the present paper, this approach permits us to get round the problem of having the enzyme from erythrocytes in homogeneous form, and of having to use relatively small amounts of blood. The data reported are clear evidence that hexokinase I in human erythrocytes is present in only one component of Mr 112000, which is similar to the value previously found for the high-Mr components of hexokinase I from human placenta. It could be speculated that hexokinases Ia, Tb and Ic probably arose by mechanism(s) other than proteolysis. Several enzymes in erythrocytes undergo multiplicity by deamination [13] or oxidation. We have performed chromatographic separation of human hexokinases Ta, Tb and Ic immediately after the preparation of cell lysate or after dialysis against reducting agents (2-mercaptoethanol and dithiothreitol), but no changes in the chromatographic pattern were observed (results not shown), making the hypothesis of a partial enzyme oxidation unlikely. A definitive answer about the mechanisms leading to the erythrocyte hexokinase microheterogeneity has still not been obtained; however, it seems to be worthwhile to work on this problem, as enzyme microheterogeneity is one of the determinants of their half-life in vivo [16] .
